Aegerion Pharma (AEGR) is Upgraded by Guggenheim to Buy

Aegerion Pharma (AEGR) is Upgraded by Guggenheim to Buy , according to the research report released to the investors. Earlier the firm had a rating of Sell on the company shares. The shares recommendation by the Brokerage Firm was released on Dec-22-2015.

Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) ended Thursday session in red amid volatile trading. The shares closed down 0.28 points or 3.03% at $8.95 with 624,266 shares getting traded. Post opening the session at $9.25, the shares hit an intraday low of $8.92 and an intraday high of $9.7499 and the price vacillated in this range throughout the day. The company has a market cap of $259 million and the number of outstanding shares has been calculated to be 28,937,476 shares. The 52-week high of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is $28.97 and the 52-week low is $8.68.

During the last several months other analysts have commented on the company rating. In the latest statement by the brokerage house, Bank of America upgrades its outlook on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Underperform. The rating by the firm was issued on November 11, 2015.

As many as 6 brokerage firms have rated Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) at 2.33. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. The stock garnered a place in the hold list of 4 stock Analysts. 2 analysts rated the company as a strong buy.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): 5 analysts have set the short term price target of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) at $19.8. The standard deviation of short term price target has been estimated at $7.53, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 31 and $13 respectively.

Aegerion Pharmaceuticals, Inc. has lost 8.21% in the last five trading days and dropped 5.69% in the last 4 weeks. Aegerion Pharmaceuticals, Inc. has dropped 49.15% during the last 3-month period . Year-to-Date the stock performance stands at -57.26%.

Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As of December 31, 2011, the Company developed its first product candidate, lomitapide, as an oral, once-a-day treatment for patients with a inherited lipid disorder called homozygous familial hypercholesterolemia (HoFH). The Company conducted a 78-week Phase III clinical trial of lomitapide in the treatment of adult patients with HoFH. The 56-week results of the trial were announced in May 2011. It completed the trial during the year ended December 31, 2011, and in January 2012, announced the 78-week results of the trial, which were consistent with the 56-week results. In 2011, the United States Food and Drug Administration (FDA) granted orphan drug designation for lomitapide in the treatment of HoFH.